OBJECTIVES: Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab
concentrations are associated with decreased duration of response. We evaluated the clinical …

Background & Aims The medical management of ulcerative colitis (UC) has improved through
the development of new therapies and novel approaches that optimize existing drugs. …

Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to provide
a consensus statement regarding the clinical utility of TDM for biologics in inflammatory …

Background & Aims Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23,
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …

Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

Background: Ustekinumab is a fully human IgG1 monoclonal antibody that blocks the
biologic activity of interleukin-12/23. Ustekinumab is approved for treatment of plaque psoriasis …

Background The aim of this study was to assess the clinical benefit and tolerability of
adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with …

Background and aims: Current endoscopic activity scores for ulcerative colitis (UC) do not
take into account the extent of mucosal inflammation. We have developed a simple …

Background Multiple studies have established the superior diagnostic accuracy of video
capsule endoscopy (VCE) for the diagnosis of small bowel (SB) Crohn's disease (CD). However…

Background Patients with inflammatory bowel disease (IBD) are at high risk for non-alcoholic
fatty liver disease (NAFLD). Longitudinal data on incident NAFLD are lacking. We …